Xarelto Is The Pharma Watchword In Bayer's 3Q Update

Despite Bayer AG's third quarter earnings call being heavily dominated by talk of the company's ongoing Monsanto acquisition and its recent deconsolidation of material science company Covestro, Xarelto stood out as the hot topic within the German firm's pharma division.

blood clot
Bayer targets 2017 regulatory filings for Xarelto in coronary artery and peripheral arterial disease

Bayer confirmed during its third quarter earnings call that it will submit regulatory applications for its blood thinner Xarelto (rivaroxaban) in coronary artery and peripheral arterial disease in the US and EU by the end of the year in order to expand the blockbuster product's label quickly in the US and Europe.

The regulatory submissions will be based on data from the large-scale COMPASS trial. The 27,000-patient study, full data for which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.